anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Of the 401 patients with resectable NSCLC treated with IMFINZI in combination with chemotherapy in the AEGEAN study, 209 (52%) patients were 65 years or older and 49 (12%) patients were 75 years or older. There were no overall clinically meaningful differences in safety or efficacy between patients ≥ 65 years of age and younger patients.

Of the 476 patients with unresectable, Stage III NSCLC treated with IMFINZI in the PACIFIC study, 45% were 65 years or older, while 7.6% were 75 years or older. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients. The PACIFIC study did not include sufficient numbers of patients aged 75 years and over to determine whether they respond differently from younger patients.

Of the 330 patients with metastatic NSCLC treated with IMFINZI in combination with tremelimumab-actl and platinum-based chemotherapy, 143 (43%) patients were 65 years or older and 35 (11%) patients were 75 years or older. There were no clinically meaningful differences in safety or efficacy between patients 65 years or older and younger patients.

Of the 262 patients with LS-SCLC treated with IMFINZI, 103 (39%) patients were 65 years or older and 15 (6%) patients were 75 years or older. There were no clinically meaningful differences in safety and efficacy between patients 65 years or older and younger patients.

Of the 265 patients with ES-SCLC treated with IMFINZI in combination with chemotherapy 101 (38%) patients were 65 years or older and 19 (7.2%) patients were 75 years or older. There were no clinically meaningful differences in safety or efficacy between patients 65 years or older and younger patients.

Of the 338 patients with BTC treated with IMFINZI in combination with chemotherapy in the TOPAZ-1 study, 158 (47%) patients were 65 years or older and 38 (11%) patients were 75 years or older. No overall differences in safety or effectiveness of IMFINZI have been observed between patients 65 years of age and older and younger adult patients.

Of the 393 patients with uHCC treated with IMFINZI in combination with tremelimumab-actl, 50% of patients were 65 years of age or older and 13% of patients were 75 years of age or older. No overall differences in safety or effectiveness of IMFINZI have been observed between patients 65 years of age and older and younger adult patients.

Of the 235 patients with endometrial cancer treated with IMFINZI with carboplatin and paclitaxel, 49% of patients were 65 years of age or older and 12% of patients were 75 years of age or older. No overall differences in safety or effectiveness of IMFINZI have been observed between patients 65 years of age and older and younger adult patients.
A classification of a level of cancer in an organism is determined by analyzing a biological sample of the organism. The biological sample comprises clinically-relevant DNA and other DNA. At least some of the DNA is cell-free in the biological sample. An amount of a first set of DNA fragments from the biological sample corresponding to each of a plurality of sizes is measured. A first value of a first parameter is calculated based on the amounts of DNA fragments at the plurality of sizes. The first value is compared to a reference value. A classification of a level of cancer in the organism is determined based on the comparison.
Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
The invention provides a means of closed exchange of implanted medical device components. An exchanger is brought into contact with the implanted medical device "in situ". The component is withdrawn from the implanted device and brought into a closed chamber of the exchanger. Without breaking the contact between implanted device and exchanger, the replacement component is then moved from its position in the exchanger, and inserted into the correct position in the implanted device. The surfaces of the implanted device are not brought into contact with the outside environment, thereby minimizing the possibility of introducing contaminants into the body during the exchange process. The invention is particularly useful for devices that are difficult to position and reposition, thus making it advantageous to exchange only an expended component, rather than the entire device.
PURPOSE:To obtain the subject monoclonal antibody, belonging to IgG3, reactive with at least one ganglioside GD3 and 3',8'-LD1, having cellulicidal activity and useful for treating, etc., cancer, etc., such as malignant melanoma derived from the neurectodermal system. CONSTITUTION:A ganglioside GD3 in which NeuAc alpha2.-8NeuAc alpha-3Gal saccharide chain is bound to the nonreducing terminal, dipalmitoylphosphatidylcholine, cholesterol, dipalmitoylphosphatidic acid and lipid A are dissolved in a solvent, which is then removed to form a lipid thin film. A buffer solution is subsequently added to stir the mixture. Thereby, an antigenic solution is prepared and administered to murine caudal vein and immunization is carried out. A splenic cell is collected and fused to a cell of a murine myeloma and the fused cell is screened and cloned. The resultant monolconed fused cell is cultured to afford the objective monoclonal antibody, belonging to IgG3, reactive with one or more gangliosides 3 and 3',8'-LD1, having the cellulicidal activity and useful for treating cancer derived from the neurectodermal system.
Accommodation is the process of adjusting focal distance to achieve a clear retinal vision by altering the shape of human crystalline lens in the eye. Accommodative responses are composed of two parts, phasic and tonic. The adequate phasic accommodation is needed to form a clear retinal image of near stimuli. The proper tonic accommodation is needed to maintain clear retinal vision after the initial phasic response. The phasic and tonic accommodative responses are mediated by the sympathetic and parasympathetic systems. Accommodative accuracy and endurance is achieved by modifying the neuromuscular connection through repetitive learning and adaptation.

Vision training has been shown effective to increase accommodative amplitude and endurance. Its efficacy is achieved by gradually increasing the difficulty of tasks that require patients to attentively process visual cues to adapt their accommodative responses. Its end goal is to induce effective and permanent adaptations to the visual environment. The process of vision training has been theorized as a bioengineering model in which the neuromuscular signal is altered through visuomotor feedback. The increase in accommodative accuracy is thought to reflect the gain of accommodative responses and the increase of accommodative endurance is the result of maintained tonic neural output.

Empirical studies have shown the Digitalisglycosides (DGS) can enhance muscular contraction and Esculin improves micro vascular circulation. Stulln eyedrops include these active ingredients and have been approved to treat visual discomfort and retinal macular diseases in Europe and China. It also has a very good safety record, without any report of adverse effects to human body for the millions of users each year. The efficacy of Stulln in treating visual discomfort might have resulted from the improved microcirculation of blood and wastes, leading to better ciliary functions. Indeed, empirical studies have shown Stulln application can improve accommodative amplitude, facility and endurance. However, Stullen itself might not produce long-term changes in neuromuscular innervation, as its ingredients can be removed from the human body within an day.

The present study tests the hypothesis that Stulln eyedrops improve accommodative functions by improving the short term accommodative facility and endurance. To test this, the investigators propose to conduct a prospective randomized control trials where participants with accommodative dysfunctions are randomly assigned to three groups: control, Stulln only and Stulln plus vision training. The investigators' theory predicts that the efficacy of Stulln will be augmented by vision training.
BACKGROUND: Numerous studies have examined associations between overweight and obesity and risk of low back pain (LBP), but the exact magnitude of these associations is not yet clear. The purpose of this work was to assess such sex-specific associations in a community-based setting in Norway, taking into account potential relationships with other risk factors.
METHODS: A cohort study was conducted combining data from two waves of the Trøndelag Health Study, HUNT3 (2006-2008) and HUNT4 (2017-2019). Separate analyses were performed of risk of chronic LBP in HUNT4 among 14,775 individuals without chronic LBP in HUNT3, and of recurrence or persistence in HUNT4 among 5034 individuals with chronic LBP in HUNT3. Relative risks were estimated in generalised linear models for overweight and obesity compared to normal weight. Body size classification was based on values of BMI computed from measurements of height and weight. Chronic LBP was defined as LBP persisting at least 3 months during last year.
RESULTS: After adjustment for age, smoking, physical activity in leisure time and work activity, analysis of risk among women produced relative risks 1.11 (95% CI 1.00-1.23) for overweight, 1.36 (95% CI 1.20-1.54) for obesity class I and 1.68 (95% CI 1.42-2.00) for obesity classes II-III. Relative risks among men were 1.10 (95% CI 0.94-1.28) for overweight, 1.36 (95% CI 1.13-1.63) for obesity class I and 1.02 (95% CI 0.70-1.50) for obesity classes II-III, the last estimate being based on relatively few individuals. Analyses of recurrence or persistence indicated similar relationships but with smaller magnitude of relative risks and no drop in risk among obesity classes II-III in men. The change in BMI from HUNT3 to HUNT4 hardly differed between individuals with and without chronic LBP in HUNT3.
CONCLUSIONS: Risk of chronic LBP increases with higher values of BMI in both sexes, although it is uncertain whether this applies to very obese men. Very obese women carry a particularly large risk. Probabilities of recurrence or persistence of chronic LBP among those already afflicted also increase with higher values of BMI. Adjustment for other factors does not influence relationships with overweight and obesity to any major extent.
Detecting breast abnormalities includes receiving a first mammographic image having original pixels. A second mammographic image is generated by enhancing the first mammographic image. Enhancing the first mammographic image includes performing the following for each original pixel in at least a subset of the original pixels. A histogram is generated for a region surrounding the original pixel, the region defined by an enhancement sliding window. Using the histogram, a value of the original pixel is revised to obtain a revised value, and the revised value is stored in the second mammographic image. A breast abnormality location is detected based on the second mammographic image.
BACKGROUND: This study sought to evaluate the safety, efficacy, and resource utilization of a pilot outpatient surgery program for total hip arthroplasty compared to traditional inpatient total hip arthroplasty performed via the posterolateral approach.
METHODS: A cohort of 68 patients from two sites were enrolled in a regional pilot project for outpatient total hip arthroplasty (THA) and matched 1:1 against a cohort of patients undergoing routine inpatient THA. Data was extracted retrospectively from patient and hospital charts including adverse events (AE), readmission within 90 days, emergency room (ER) visits, patient calls, patient-reported outcome measures, length of stay, and multiple surgical variables.
RESULTS: The outpatient group had a mean hospital stay of 13 hours, whereas the inpatient group had a mean of 58 hours (p<0.001). Three outpatients and four inpatients experienced post-op complications. Three inpatients and one outpatient visited the ER within 8 weeks of surgery. No difference in pre-operative hemoglobin (p = 0.210), or surgical blood loss (p = 0.550) was found between study groups. There was no difference found between groups regarding Oxford-12 Hip Score improvement, nor satisfaction at six months, one and two years (p>0.125).
CONCLUSION: This study demonstrates that outpatient THA using the posterolateral approach is as safe and effective as inpatient THA for overall healthy and carefully screened patients, based on the low rate of AEs observed and similar patient outcomes reported. Significantly reduced time in hospital demonstrates the reduced healthcare resources associated with outpatient THA.
Patients after surgery are liable to suffer from moderate to severe acute pain and refractory chronic pain, which would lead to serious somatic and psychological suffering. Its successful treatment is a great challenge for pain physicians. To date, the mechanism of pain chronification after surgery remains unclear. Further, it is still lack of efficient preventive and therapeutic measures for this chronic pain. The project will apply the methods of clinical observation and animal experiment, (1) to collect the cognitive function data preoperatively and early postoperatively, as well as the pain score data at multiple time points pre- and postoperatively, and to observe the role of the degree of recovery of early postoperative cognitive function on acute pain and chronic pain after thoracic surgery. (2) to collect the resting-state electroencephalography (EEG) preoperatively, and to assess the role of EEG index system on the prediction of the degree of recovery of early postoperative cognitive function as well as the acute pain and chronic pain after thoracic surgery. The project will be able to determine the relationships between the degree of recovery of early postoperative cognitive function, as well as preoperative resting-state EEG indices and postoperative acute pain and chronic pain, and clarify the neural mechanism of acute pain and chronic pain after surgery. The expected outcomes of this study can contribute to early identification of the patients who are liable to develop into acute pain and chronic pain after surgery, and give them reasonable intervention in time, and provide effective solutions for the acute pain and chronic pain after surgery.
Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A "BMF-form" will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
A system for monitoring people's activity and/or health while at the same time preserving their privacy. Monitoring is accomplished by detecting state of people's electronic devices, e.g., a smart phone. When use of the monitored device deviates from an expected use an alert is automatically sent to a monitoring device. The relationships between users are optionally maintained in a social network. Privacy is strictly protected by reporting only deviations from use according to rules set by the person being monitored. Optionally an activity monitoring system receives data from multiple sources such as a home security system, IoT devices and a smartphone. The use of multiple data sources provides an improved activity monitoring system capable of distinguishing normal activity from abnormal activity that may be indicative of a physical or mental health condition. Variations in the monitored activity are used to identify potential health issues for the user. If a health issue is identified, an alert may be sent to a remote third party. A human augmented positive feedback loop is used to generate data for training of machine learning systems.
The study was a double-blind randomized controlled trial to determine the protective effect of low-dose continuous furosemide perioperative in cardiac surgery patients with mild to moderate kidney dysfunction. Ethical clearance for the study was approved by Institutional Review Board of National Cardiovascular Center Harapan Kita. Patients eligible for the study was recruited and written informed consent was obtained after clear explanation of the study. Allocation of furosemide and control group was done using simple computer randomization by staff who was not involved in the study. Furosemide infusion and normal saline was prepared by independent pharmacist blinded to the study. Furosemide solution was prepared to contain 40 mg of furosemide diluted with normal saline to a total volume of 40 cc (1 mg / 1 cc) and control solution was prepared to contain only 40 cc of normal saline. Both solution was packaged in 50-cc syringe and prepared in similar fashion. The solution was administered after induction of anesthesia with rate of 2 cc per hour for 12 hours.

Baseline participant were collected before surgery. All cardiac surgery procedure was done in concordance to hospital standard operating procedure. The primary outcomes of the study were glomerular filtration rate, need of diuretic infusion dose after intervention, need of renal replacement therapy and the secondary outcomes were ICU length of stay and in hospital mortality. The calculated sample size estimated was 41 participants per group, accounting for drop-out rate, expected sample size was 45 participants per group (90 participants in total).
One of the most common problems many babies encounter is neonatal jaundice. The symptoms are yellowing of the skin or eyes because of bilirubin (from above 2.0 to 2.5 mg/dL in the blood). If left untreated, it can lead to serious neurological complications. Traditionally, jaundice detection has relied on invasive blood tests, but developing non-invasive biosensors has provided an alternative approach. This systematic review aims to assess the advancement of these biosensors. This review discusses the many known invasive and non-invasive diagnostic modalities for detecting neonatal jaundice and their limitations. It also notes that the recent research and development on non-invasive biosensors for neonatal jaundice diagnosis is still in its early stages, with the majority of investigations being in vitro or at the pre-clinical level. Non-invasive biosensors could revolutionize neonatal jaundice detection; however, a number of issues still need to be solved before this can happen. These consist of in-depth validation studies, affordable and user-friendly gadgets, and regulatory authority approval. To create biosensors that meet regulatory requirements, additional research is required to make them more precise and affordable.
Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
<P>PROBLEM TO BE SOLVED: To obtain an antibacterial agent having excellent antibacterial actions on bacteria of Corynebacterium sp. considered as a cause of a body odor (osmidrosis axillae) and to obtain an external composition comprising the antibacterial agent.  <P>SOLUTION: The antibacterial agent against the bacteria of the Corynebacterium sp. comprises methyl p-hydroxybenzoate as an active ingredient. The external composition comprises the antibacterial agent.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
PURPOSE:To efficiently produce L-threo-hydroxyaspactic acid, useful, e.g. as a medicine or an intermediate for medicines by culturing an L-threo- hydroxyaspartic acid-producing microorganism belonging to Papularia in an L-aspartic acid-containing medium and subsequently collecting the product. CONSTITUTION:A microorganism [e.g. Papularia arundines NF 00779 strain (FERM-P-13773)] belonging to Papularia and capable of producing L-threo- hydroxyaspartic acid is inoculated in an L-aspartic acid-containing medium and subjected to shaking culture at 27 deg.C under 220 rotation/min for 3 day. This cultured solution is centrifuged and the resultant supernatant is collected. The collected supernatant is brought into contact with a strong cation-exchange resin and the adsorbed substances are subsequently eluted with an aqueous solution of pH 3 to 8. The products are separated from this elute, thus efficiently producing the objective L-threo-hydroxyaspartic acid having an antimicrobial activity and useful, e.g. as a medicine or an intermediate for medicines.
Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into two protocols: 1) Protocol A and 2) Protocol B. In their first session, participants in Protocol B will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the sham condition. Testing will then be repeated. In the second session, after baseline testing, participants will receive the experimental condition (instead of the sham condition). Testing will then be repeated.
Group/cohort/Arm 1 (participating 21 volunteers): Eprex® injection 4,000 IU will be administered subcutaneously on Day 1; and wash out for 4 weeks. GBPD002 injection 4,000 IU/1 mL will be administered subcutaneously on Day 29.
PROBLEM TO BE SOLVED: To obtain an isoleucine-containing composition that can improve stability thereof, particularly the stability at a temperature near the body by admixing a specific compound to medicines, cosmetics, food products and the like. SOLUTION: An isoleucine (or its anhydride) and an amine responding to the compound to be prepared are subjected to condensation reaction using a peptide synthesis reagent, then the free amino groups are acylated, when necessary, and purified, when necessary, to prepare the objective isoleucine derivative of formula I [R1 is H, (subjected) benzyloxycarbonyl; R2 is a 8-22C including cyclic structures) straight or branched chain alkyl, alkenyl; n is 1-8]. typically N-(benzyloxycarbonyl)isoleucinestearylamide of formula II. This compound is admixed to cosmetics, medicines and the like, particularly of high content of oily component. The amount of the compound of formula I is preferably 0.1-100 pts.wt. per 1 pt.wt. of the oily component.
Initial Treatment— Administer fluoxetine 60 mg/day in the morning. For some patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically studied in patients with bulimia. In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of Bulimia Nervosa, patients were administered fixed daily fluoxetine doses of 20 or 60 mg, or placebo [see Clinical Studies (14.3)] . Only the 60 mg dose was statistically significantly superior to placebo in reducing the frequency of binge-eating and vomiting. 

  


Periodically reassess to determine the need for maintenance treatment.